← العودة إلى الصفحة الرئيسية
الولايات المتحدة · منصات وبيانات · MarketBeat

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

نشره MarketBeat · الولايات المتحدة منذ 1 س

Novartis (NYSE:NVS) presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton’s tyrosine kinase inhibitor reduced relapse rates…

اقرأ المقال كاملًا على MarketBeat سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.marketbeat.com)

يستحق القراءة أيضًا

The Motley Fool

SpaceX Q3 Sales Rose 161% in Q3. Here's What Starlink, Starship, and AI Results Reveal About the Stock.

 Seeking Alpha

JetBlue creditors hire restructuring advisors as bonds, stock drops - WSJ

 Investing.com

Boeing 777 freighter output halted for two months over supplier row - Reuters

 MarketWatch

‘I don’t feel sorry for myself’: I’m 64 and will be renting for the rest of my life. Is that so bad?

 Yahoo Finance

Paisalo Digital Ltd (BOM:532900) (Q2 2027) Earnings Call Highlights: AUM Surges 33% as Asset ...

 Morningstar

The Ensign Group, Inc. Notice of December 7, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline